Macular And Choroidal Thickness After Intracameral Moxifloxacin For Prevention Of Postcataract Endophthalmitis

Purpose: To determine any changes in macular or choroidal thickness associated with the use of intracameral moxifloxacin as postcataract endophthalmitis prophylaxis.Setting: University of Campinas, Campinas, Sao Paulo, Brazil.Design: Prospective, randomized, partially masked, single-site clinical trial.Methods: Phacoemulsification surgery patients in the experimental group (Group A) received a 0.03 mL intracameral injection of undiluted moxifloxacin from a sealed bottle immediately after phacoemulsification surgery (150 mu g in 0.03 mL-Vigamox solution), whereas the control group (Group B) did not. Investigators evaluated in masked fashion macular and choroidal thickness using spectral-domain optical coherance tomography preoperatively and postoperatively.Results: A total of 93 patients were included (48 in Group A and 45 in Group B). Baseline parameters were similar between the groups. Either of the 2 parameters assessed differed statistically between the groups or preoperatively vs postoperatively. On postoperative day 30, central macular thickness was 8.85 +/- 14.78 mu m in Group A and 10.26 +/- 22.44 mu m in Group B (P = .7232); choroidal thickness as measured by enhanced depth imaging (EDI) was 1.45 +/- 16.13 mu m in Group A and 3.74 +/- 16.15 in Group B (P = .5017). On postoperative day 60, central macular thickness was 19.53 +/- 39.28 mu m in Group A and 17.14 +/- 53.68 mu m in Group B (P = .8363); EDI was 5.08 +/- 21.96 mu m in Group A and 5.24 +/- 15.8 in Group B (P = .9752).Conclusions: The application of intracameral injection of 0.03 mL of undiluted 0.5% moxifloxacin during phacoemulsification surgery as endophthalmitis prophylaxis induced no changes in macular or choroidal thickness. Copyright (C) 2020 Published by Wolters Kluwer on behalf of ASCRS and ESCRS